CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,477 shares of the company’s stock after purchasing an additional 231 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in CRISPR Therapeutics were worth $586,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its position in CRISPR Therapeutics by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after acquiring an additional 19,094 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of CRISPR Therapeutics by 0.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock valued at $34,025,000 after purchasing an additional 6,635 shares during the period. Farallon Capital Management LLC acquired a new stake in CRISPR Therapeutics during the 2nd quarter valued at $28,625,000. Baillie Gifford & Co. increased its stake in CRISPR Therapeutics by 2.4% during the 2nd quarter. Baillie Gifford & Co. now owns 405,425 shares of the company’s stock worth $21,897,000 after buying an additional 9,510 shares during the period. Finally, Capital Advisors Inc. OK lifted its holdings in CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after buying an additional 22,583 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CRSP. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Wednesday. Barclays cut their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Chardan Capital reissued a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $77.93.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This represents a 13.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,382 shares of company stock valued at $2,744,179 over the last 90 days. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Trading Down 3.6 %

CRSP opened at $43.78 on Friday. CRISPR Therapeutics AG has a twelve month low of $42.86 and a twelve month high of $91.10. The stock has a market cap of $3.74 billion, a PE ratio of -15.47 and a beta of 1.62. The business’s 50 day moving average is $48.79 and its 200-day moving average is $51.19.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the previous year, the business earned ($1.41) EPS. As a group, analysts forecast that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.